HYPERTRIGLYCERIDEMIA AS A RISK FACTOR FOR NON–ALCOHOLIC FATTY LIVER DISEASE

Authors

  • Sarwat Abbasi Department of Biochemistry, Ayub Medical College, Abbottabad, Khyber Pakhtunkhwa, Pakistan.
  • Saadia Sadiq Department of Biochemistry, Abbottabad International Medical College, Abbottabad, KPK, Pakistan.
  • Sara Jadoon Department of Anatomy, Ayub Medical College, Abbottabad, Khyber Pakhtunkhwa, Pakistan.
  • Salma Shazia Department of Forensic Medicine, Ayub Medical College, Abbottabad, Khyber Pakhtunkhwa, Pakistan.
  • Haroon Ur Rashid Department of Pathology Women Medical College, Abbottabad, Khyber Pakhtunkhwa, Pakistan.
  • Amjad Farooq Department of Surgery, Ayub Medical Institute, Abbottabad, Khyber Pakhtunkhwa, Pakistan.
  • Zahoor Ahmed Department of Biochemistry, Khyber Medical College, Peshawar, Khyber Pakhtunkhwa, Pakistan.

DOI:

https://doi.org/10.33279/jkcd.v15i01.684

Keywords:

Hepatic disorder, Hypertriglyceridemia, NAFLD

Abstract

Objectives: To determine increased triglyceride levels as a potential cause of development of non–alcoholic fatty liver disease.
Materials and Methods: This cross sectional study was conducted at Ayub Medical Institute, Abbottabad. A well designed questionnaire was designed. Subjects between 40–60 years age group were selected after informed consent and all the data was saved confi dentiality. Data accumulated and examined with the help SPSS version 22.
Results: Among patients with hepatic steatosis 28 (56.0%) have normal serum triglyceride levels while 22 (44.0%) have high triglyceride levels. Among individuals with no fatty infi ltration 41 (82.0%) have normal triglyceride level while only 9 (18.0%) have elevated serum triglyceride levels. 27 (54.0%) obese patients and 17 (34.0%) overweight individuals have fatty liver disease hence giving a outstanding p-value of ˂0.001 with chi-square test between NAFLD and BMI.
Conclusion: Hypertriglyceridemia was found as a risk factor for non–alcoholic fatty liver disease (NAFLD).

References

QQ Zhang, LG Lu. Nonalcoholic Fatty Liver Disease: Dyslipidemia, Risk for Cardiovascular Complications, and Treatment Strategy; J Clin Transl Hepatol. 2015 Mar; 3(1): 78–84.

Kalra S, Vithalani M, Gulati G, Kulkarni CM, Kadam Y,Pallivathukkal J, et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT) J Assoc Physicians India. 2013;61: 448–453.

Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert OpinPharmacother.2014; 15:493–503.

Alshamiri M, Ghanaim MMA, Barter P, Chang KC,Li JJ, Matawaran BJ ,et al. Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East. Int J Gen Med. 2018; 11:313–22.

Loria P,Marchesini G,Nascimbeni F,Ballestri S,Maurantonio M, Carubbi F, et al. Cardiovascular risk, lipidemic phenotype and steatosis.A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis.2014; 232(1):99–109.

Chatrath H, Vuppalanchi R, Chalasani N.Dyslipidemia in patients with nonalcoholic fatty liver disease 2012 Feb; 32(1):22-9.doi: 10.1055/s-0032-1306423.Epub 2012 Mar 13.

Speliotes EK, Massaro JM, Hoff mann U, Vasan RS, Meigs JB, Sahani DV,et al.Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study.Hepatology.2010; 51: 1979–1987.

Liu H, Lu HY.Nonalcoholic fatty liver disease and cardiovascular disease. World J Gastroenterol.2014; 20: 8407–8415.

Xing J; Guan X; Zhang Q; Chen S; Wu S; Sun X. Triglycerides Mediate Body Mass Index and Nonalcoholic Fatty Liver Disease: A Population-Based Study. (2021 March 29) 14 (2): 190–196.

Badawi A, Klip A, Haddad P, Cole DE, Bailo BG, El-Sohemy A, et al. Type 2 diabetes mellitus and inflammation: prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes.2010 May; 3:173–86.

Bray GA, Clearfi eld MB, Fintel DJ, Nelinson DS. Overweight and obesity: the pathogenesis of cardiometabolic risk. Clin Cornerstone. 2009; 9 (4):30–40.

Chalasani N, Younossi, Lavine J, Diehl AM, Brunt EM, Cusi K, et al; American Association for the Study of Liver Diseases; American College of Gastroenterology; American Gastroenterological Association. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association .Am J Gastroenterol. 2012 Jun;107(6):811–26.

Yu J, Shen J, Sun TT, Zhang X, Wong N. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol. 2013 Dec; 23(66 Pt B):483–91.

Dyson J, Jaques B, Chattopadyhay D, Lochan R, Graham J, Das D, et al Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol.2014 Jan; 60 (1):110–7.

Lonardo A, Mantovani A, Lugari S,Targher G. Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. Ann Hepatol. 2020; 19(4):359–66.

Klop B, ElteJW, Cabezas MC. Dyslipidemia in obesity; mechanism and potential targets. Nutrients.2013 Apr 12;5(4):1218-40.

Huh Y, Cho YJ, Nam GE.Recent Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease.J Obes Metab Syndr. 2022 Mar 30; 31(1):17-27.

Söderberg C, Stål P, Askling J, Glaumann H, Lindberg G, Marmur J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology.2010; 51:595–602.

Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology.2006; 44: 865–873.

Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, et al. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease.A case -control study. Dig Liver Dis. 2002; 34(3):204–11.

Souza MR, Diniz MF, Medeiros JE, Araujo MS. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol.2012; 49:89–96.

Hu Y, Liu J, Dong , Xu Y,Leng S, Wang G. Clinical Study of Serum Homocysteine and Non-Alcoholic Fatty Liver Disease in Euglycemic Patients.Med Sci Monit.2016 Nov; 22:4146–51.

Grander C, Grabherr F, Moschen AR, Tilg H. Non-Alcoholic Fatty Liver Disease:Cause or Eff ect of Metabolic Syndrome.Visc Med. 2016 Oct; 32 (5):32934.

Hsiao PJ, Kuo KK, Shin SJ, Yang YH, Lin WY, Yang JF, et al. Signifi cant correlations between severe fatty liver and risk factors for metabolic syndrome. J Gastroenterol Hepatol.

Tutunchi H, Saghafi -Asl M, Asghari-Jafarabadi M, Ostadrahimi A .The relationship between severity of liver steatosis and metabolic parameters in a sample of Iranian adults.BMC Res Notes. 2020; 13(1):218.

Nogueira-de-Almeida CA, Mello ED. Correlation of body mass index Z-scores with glucose and lipid profiles among overweight and obese children and adolescents. J Pediatr.2018;94 (3):308–12

Dejavitte RAS, Enes CC, Nucci LB. Prevalence of metabolic syndrome and its associated factors in overweight and obese adolescents. J Pediatr Endocrinol Metab.2020; 33(2):233–9.2007; 22(12):2118-23.

Downloads

Published

2025-03-18

How to Cite

Abbasi, S. ., Sadiq, S. ., Jadoon, S. ., Shazia, S., Rashid, H. U., Farooq, A., & Ahmed, Z. (2025). HYPERTRIGLYCERIDEMIA AS A RISK FACTOR FOR NON–ALCOHOLIC FATTY LIVER DISEASE. JOURNAL OF KHYBER COLLEGE OF DENTISTRY, 15(01), 58–62. https://doi.org/10.33279/jkcd.v15i01.684

Issue

Vol. 15 No. 01 (2025): Journal of Khyber College of Dentistry, Peshawar.

Section

Original Article

License

Copyright (c) 2024 Sarwat Abbasi, Saadia Sadiq, Nadia Haleem, Salma Shazia, Haroon Ur Rashid, Amjad Farooq, Zahoor Ahmed

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format
  2. Adapt — remix, transform, and build upon the material
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. NonCommercial — You may not use the material for commercial purposes .
  3. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.